Overview

A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia

Status:
Terminated

Trial end date:
2017-08-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to examine the safety and efficacy of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukemia (AML).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Azacitidine
Cytarabine
Decitabine